Total body iron overload occurs most often due either to hereditary hemochromatosis or to repeated transfusions in patients with severe anemia. Hereditary hemochromatosis is the more common of the two by far.
Hereditary haemochromatosis reflects a fractional increase in dietary iron absorption (Cox and Peters, 1978) (Cox and Peters, 1980) (Lynch et al., 1989). Tissue iron reaches dangerous levels after thirty or forty years. The gene responsible for hereditary haemochromatosis, HFE, resides on chromosome 6. Discovered in 1996, the gene encodes a protein that is homologous to the Class I HLA antigens (Feder, et al., 1996). The alteration in HFE protein that produces hereditary haemachromatosis involves the mutation of a cysteine to a leucine at position 282 (C282Y). People who have one copy of the mutant HFE gene are carriers who only rarely develop iron overload (usually in association with a second defect.) People with two copies of the mutant protein can develop iron overload and the myriad of problems that it can produce (see below). Nearly 90% of people who have hereditary haemochromatosis have the C282Y mutation in HFE (Nielson, et al., 1998).
Only recently have investigators gained insight into the mechanism by which the mutation in HFE alters cellular iron metabolism. Iron in the circulation is bound to the protein, transferrin, which maintains it in a non-toxic state. Cells contain receptors for transferrin on their plasma membranes which mediate cellular iron uptake. Transferrin receptors bind iron-transferrin complexes which are taken into endosomes. Iron is separated from transferrin in the endosome, and is shuttled into the interior of the cell. The iron-free transferrin (apotransferrin) is recycled into the circulation and is free to bind and transport additional iron atoms. The HFE protein associates with the transferrin receptor and prevents internalization of iron-transferrin complex into cells (Gross, et al., 1998). The HFE protein, in effect, acts as a brake on cellular iron uptake.
The C282Y mutation in HFE disrupts the folding of the protein (Lebron, et al., 1998). The mutant protein does not associate with the transferrin receptor and does not dampen iron uptake by cells. These insights do not fully explain the increase in gastrointestinal iron absorption, which is the root of hereditary hemochromatosis. They are, however, the first observations that mechanistically connect HFE and iron metabolism. Improved understanding of the complex process of intestinal iron absorption should surmount this shortcoming.
Hereditary hemachromatosis is remarkably common. About 10% to 12% of people of European background are heterozygous for the condition (Douabin, et al., 1999). The number of people who are homozygous for the condition approaches one in three hundred. This makes hereditary hemochromatosis one of the most prevalent genetic conditions in the world. Interestingly, the clinical expression of the disorder is less than frequency calculations predict. Variable penetrance, prerhaps related to secondary genetic or environemental conditions must influence clinical manifestations.
With transfusional iron overload, the senescent red cells are destroyed by reticuloendothelial cells. The iron is deposited onto transferrin, the protein responsible for iron transport in the blood. From here, the iron is distributed to all body tissues. With transfusional iron overload, excess iron occurs both in the reticuloendothelial cells and parenchymal cells. In contrast, with hereditary hemochromatosis the iron is placed directly onto transferrin and from there moves to the tissues. The distinguishing feature between transfusional iron overload and hereditary hemochromatosis is the presence of large deposits of iron in the reticuloendothelial cells with the former. The pattern of organ injury is the same with the two.
Hematoxylin and eosin staining reveals a brownish pigment in the hepatocytes which Perl's Prussian blue staining unmasks as iron (Hultcrantz and Glaumann, 1982). Large amounts of iron are also deposited in Kupfer cells of patients with transfusional iron overload. Electron microscopy reveals substantial hemosiderin aggregates in addition to large quantities of ferritin.
As with many other conditions that injure the liver, hepatic damage secondary to excessive iron deposition produces fibrosis. With long standing hemochromatosis, micronodular cirrhosis can also develop. Hemosiderotic liver damage produces very little inflammation. Consequently, significant hepatic iron deposition and even fibrosis can occur with very little increase in the serum transaminase levels. Disturbances in liver synthetic function indicate advanced disease.
The physical examination is surprisingly benign even in patients with heavy cardiac iron deposition. Once evidence of cardiac failure appears, however, heart function rapidly deteriorates, often without response to medical intervention. Biventricular failure produces pulmonary congestion, peripheral edema, and hepatic engorgement. Vigorous iron extrication has reversed this potentially lethal complication on occasion (Rahko et al., 1986).
Iron deposition in the Bundle of His and the Purkinje system produces conduction defects (Buja and Roberts, 1971) (Olson et al., 1987). Sudden death is common in these patients, presumably due to arythmias. At one time, patients treated with the chelator desferrioxamine for transfusional iron overload received supplements of ascorbic acid in the range of 15 to 30 mg/kg per day to promote iron mobilization (O'Brien, 1977). Reports of sudden death prompted cessation of this practice (Nienhuis, 1981). At lower doses (2 to 4 mg/kg), ascorbic acid is a safe adjunct to chelation therapy in patients with transfusional iron overload.
Cardiac dysfunction can occur with very little tissue iron deposition. The total quantity of iron is less important than the unbound, or "toxic" iron subset. The concentration of unbound iron in tissues is extremely small, and virtually impossible to measure. This "toxic" iron is precisely the component bound and neutralized by iron chelators (in the case of desferrioxamine, the association constant is about 1032, see below). Therefore, cardiac damage is best prevented in patients with transfusional iron overload by maintaining a constant low level of chelator in the circulation (and consequently in the tissues, where the protection is rendered.) Chick cardiac myocytes in culture contract spontaneously. Iron salts added to the culture medium poison the cells and abrogate this function. Desferrioxamine chelates extracellular, and importantly intracellular iron, and restores myocyte contractility (Link G, et al. 1985).
Echocardiography in children and radionuclide ventriculography in adults are the most useful non-invasive diagnostic techniques. The echocardiographic abnormalities correlate roughly with the number of transfusions. Exercise radionuclide ventriculograms are particularly sensitive in the detection of cardiac dysfunction in patients with iron overload (Leon et al., 1979).
Pituitary dysfunction produces a plethora of endocrine disturbances (Costin et al., 1979). Reduced gonadotropin levels are common. When coupled with primary reductions in gonadal synthesis of sex steroids, this phenomenon delays sexual maturation in some children with transfusional iron overload. Secondary infertility is common (Schafer et al., 1981). Although Addison's syndrome is uncommon with iron overload, production of ACTH is occasionally deficient. A metapyrone stimulation test shows delayed or diminished pituitary secretion of ACTH (Schafer et al., 1985).
Thyroid function is usually well-preserved in patients with iron overload. In contrast, parathyroid activity is frequently compromised. Functional hypoparathyroidism can be demonstrated in many patients by inducting hypocalcemia with an intravenous bolus of ethelyenediamine tetraacetic acid (EDTA) while monitoring the production of parathyroid hormone (Gertner et al., 1979).
Arthropathy, a common feature with hereditary hemochromatosis, is rare in patients with secondary iron overload (Mathews and Williams, 1987). The large joints, such as the hips are affected most commonly (Axford et al., 1991). Decades of iron deposition in articular cartilage in hereditary hemochromatosis is the presumed cause of this condition. Chondrocalcinosis is a late but characteristic feature of the arthropathy seen in hereditary hemochromatosis. Other troubling musculoskeletal problems include severe, recurrent cramps and disabling myalgias. Muscle biopsy shows iron deposits in the myocytes, but the pathophysiologic connection to the pain and cramps is unclear.
Bone disease, manifested as osteoporosis, is a significant problem in patients with thalassemia. Bone marrow expansion often thins the bone cortex, making these patients very susceptible to fractures. The etiology of the bony disorder in patients with thalassemia is unclear. One possible contributor is the desferrioxamine used to prevent iron overload. The chelator has a very high specificity for iron. It may, however, chelate a small amount of the calcium that is necessary for the production of new bone. Over the years, a very low rate of mineral scavenging from bone by desferrioxime could contribute to osetoporosis.
Pulmonary hypertension is a problem that has been widely recognized only recently in patients with iron overload. A number of reports have involved patients with thalassemia major or thalassemia intermedia with iron overload (Aessopos, et al., 1995) (Grisaru D,et al., 1990) (Koren, et al., 1987). No report exists of similar problems in people with iron overload from other causes, such as hereditary hemochromatosis. The combination of iron overload in the pulmonary tissues and high blood flow through the pulmonary vascular bed may be at fault. More work is needed to clarify these issues.
The very high transferrin saturations attained in patients with iron overload compromise the bacteriostatic properties of the protein. Iron sequestration is not a frontline defense against microbes. Therefore, iron overload does not produce the susceptibility to infection seen with defects in more central systems (e.g., chronic granulomatous disease.) Nonetheless, a number of infections, often with unusual organisms, have been reported in patients with iron overload (Abbott et al., 1986) (Brennan et al., 1983) (Bullen et al., 1991) (Capron et al., 1984):
Sideroblastic anemia often produces neutropenia or neutrophil dysfunction. Host defense is compromised even further in patients with sideroblastic anemia who develop secondary iron overload. Although aggressive antimicrobial therapy is often successful, some infections, such as the mucormycosis produced by Rhizopus oryazae, are almost uniformally fatal.
The iron chelator, desferrioxamine, has also been implicated in opportunistic infection with unusual organisms such as Rhizopus orayzae, the cause of mucormycosis, in some patients with iron overload (Boelaert et al., 1988) (Rex et al., 1988) (Daly et al., 1989). Streptomyces pilosis synthesizes this siderophore when grown in an iron-deficient environment. Desferrioxamine is released in the vicinity of these microbes, binds iron, and returns the element to the microorganisms to support growth and replication. Some pathogenic bacteria and fungi can utilize desferrioxamine-bound iron to promote their growth, thereby enhancing the risk of severe infection (Robins-Browne and Prpic, 1985).
The question of when to begin chelation therapy in a patient with transfusional hemochromatosis lacks a simple answer (Fargion et al., 1982). The decision must be carefully individualized. Serious infection in patients treated with desferrioxamine is uncommon, and the benefits of therapy to prevent iron-induced organ damage generally outweigh the risk of infectious complications.
Aessopos A, Stamatelos G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos, D. (1995). Pulmonary hypertension and right heart failure in patients with ß- thalassemia intermedia. Chest 107, 50-53.
Axford, J., Bomford, A., Revell, P., Watt, I., Williams, R., and Hamilton, E. (1991). Hip arthropathy in genetic hemochromatosis. Radiographic and histologic features. Arthritis Rheum 34, 357-61.
Bassett, M., Halliday, J., and Powell, L. (1981). HLA typing in idiopathic hemochromatosis: distinction between homozygotes and heterozygotes with biochemical expression. Hepatology 1, 120-126.
Bassett, M., Halliday, J., and Powell, L. (1986). Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6, 24-28.
Boelaert, J., van Roost, G., Vergauwe, P., Verbanck, J., de Vroey, C., and Segaert, M. (1988). The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clinical Nephrology 29, 261-266.
Bomford, A., and Williams, R. (1976). Long term results of venesection therapy in idiopathic haemochromatosis. Quarterly Journal of Medicine 45, 611-23.
Bonkovsky, H. (1991). Iron and the liver. American Journal of Medical Science 301, 32-43.
Brennan, R., Crain, B., Proctor, A., and Burack, D. (1983). Cunninghamella: a newly recognized cause of rhinocerebral mucormycosis. American Journal of Clinical Pathology 80, 98-102.
Buja, L., and Roberts, W. (1971). Iron in the heart. American Journal of Medicine 51, 209-221.
Bullen, J. J., Spaulding, P. B., Ward, C. G., and Gutteridge, J. M. C. (1991). Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Archives of Internal Medicine 151, 1606-1609.
Capron, J., Capron-Chivrac, D., Tossou, H., Delamarre, J., and Eb, F. (1984). Spontaneous Yersinia enterocolitica peritonitis in idiopathic hemochromatosis. Gastroenterology 87, 1372-1375.
Conte, D., Piperno, A., Mandelli, C., Fargion, S., Cesana, M., Brunelli, L., Ferrario, L., Velio, P., Zaramella, M., Tiribelli, C., and al, e. (1986). Clinical, biochemical and histological features of primary haemochromatosis: a report of 67 cases. Liver 6, 310-5.
Costin, G., Kogut, M., Hyman, C., and Ortega, J. (1979). Endocrine abnormalities in thalassemia major. American Journal of Disease of Childhood 133, 497-502.
Cox, T., and Peters, T. (1978). Uptake of iron by duodenal biopsy specimens from patients with iron-deficiency anaemia and primary haemochromatosis. Lancet 1, 123-4.
Cox, T., and Peters, T. (1980). In vitro studies of duodenal iron uptake in patients with primary and secondary iron storage disease. Q J Med 49, 249-57.
Daly, A., Velazquez, L., Bradley, S., and Kauffman, C. (1989). Mucormycosis: association with deferoxamine therapy. American Journal of Medicine 87, 468-471.
Douabin V, Moirand, R, Jouanolle A, Brissot P, Le Gall J, Deugnier Y, David V. 1999. Polymorphisms in the HFE Gene. Hum Here 49: 21-26.
Edwards, C., Dadone, M., Skolnick, M., and Kushner, J. (1982). Hereditary haemachromatosis. Clinical Haematology 11, 411-435.
Fargion, S., Taddei, M., Gabutti, V., Piga, A., DiPalma, A., Capra, L., Fontanelli, G., and Avanzini, A. (1982). Early iron overload in beta-thalassaemia major: when to start chelation therapy? Archives of Diseases of Childhood 57, 929.
Feder, J., Gnirke, A., Thomas, W., Tsuchihashi, Z., and al., e. (1996). A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics 13, 399-408.
Fitchett, D., Coltart, D., Littler, W., MJ, L., Trueman, T., Gozzard, D., and Peters, T. (1980). Cardiac involvement in secondary hemochromatosis. Cardiovascular Research 14, 7199-7284.
Flynn, D., Fairney, A., Jackson, D., and Clayton, B. (1976). Hormonal changes in thalassemia major. Archives of Diseases of Childhood 51, 828-836.
Gertner, J., Broadus, A., Anast, C., Grey, M., Pearson, H., and Genel, M. (1979). Impaired parathroid response to induced hypocalcemia in thalassemia major. Journal of Pediatrics 95, 210-213.
Grisaru D, Rachmilewitz EA, Mosseri M, Gotsman M, Lafair JS, Okon E, Goldfarb A, Hasin Y. (1990) Cardiopulmonary assessment in beta-thalassemia major. Chest 98, 1138-1142.
Gross CN, Irrinki A, Feder JN, Enns CA. 1998. Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation. J. Biol. Chem. 273: 22068-22074.
Hultcrantz, R., and Glaumann, H. (1982). Studies on the rat liver following iron overload. Biochemical analysis following iron mobilization. Laboratory Investigation 46, 383-393.
Koren, A., Garty, I., Antonelli, D., and Katzuni, E. (1987). Right ventricular cardiac dysfunction in beta-thalassemia major. American Journal of Diseases of Childhood 141, 93-96.
Lawrence 3d, T., Biggers, C., and Simonton, P. (1977). Bacteriostatic inhibition of Klebsiella pneumoniae by three human transferrins. Ann Hum Biol 4, 281-4.
Lebron JA, Bennett MJ, Vaughn, DE, Chirino AJ, Snow PM, Mintier GA, Feder JN, Bjorkman PJ. 1998. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 93: 111-123.
Leon, M., Borer, J., Bacharach, S., Green, M., Benz, E., Griffith, P., and Nienhuis, A. (1979). Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. New England Journal of Medicine 301, 1143-1148.
Link G, Pinson A, Hershko C . 1985. Heart cells in culture: a model of myocardial iron overload and chelation. J. Lab. Clin. Med. 106: 147-153.
Liu, P., and Olivieri, N. (1994). Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther 8, 101-10.
Lynch, S., Skikne, B., and Cook, J. (1989). Food iron absorption in idiopathic hemochromatosis. Blood 74, 2187-93.
Mathews, J., and Williams, H. (1987). Arthritis in hereditary hemochromatosis. Arthritis Rheum 30, 1137-41.
Nielsen P, Carpinteiro S, Fischer R, Cabeda JM, Porto G, Gabbe EE. 1998. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Brit. J Haematol. 103:842-845.
Nienhuis, A. (1981). Vitamin C and Iron. New England Journal of Medicine 304, 170-171.
O'Brien, R. (1977). Iron overload: clinical and pathologic aspects in pediatrics. Seminars in Haematology 14, 115-125.
Olson, L., Edwards, W., McCall, J., Ilstup, D., and Gersh, B. (1987). Cardiac iron deposition in idiopathic hemochromatosis: Histologic and analytic assessment of 14 hearts from autopsy. Journal of the American College of Cardiology 10, 1239-1243.
Rahko, P., Salerni, R., and Uretsky, B. (1986). Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. Journal of the American College of Cardiology 8, 436-440.
Reiter, B., Brock, J., and Steel, E. (1975). Inhibition of Escherichia coli by bovine colostrum and post-colostral milk. II. The bacteriostatic effect of lactoferrin on a serum susceptible and serum resistant strain of E. coli. Immunology 28, 83-95.
Rex, J., Ginsberg, A., Fries, L., Pass, H., and Kwon-Chung, K.-J. (1988). Cunninghamella bertholletiae infection associated with deferoxamine therapy. Reviews of Infectious Diseases 10, 1187-1194.
Robins-Browne, R., and Prpic, J. (1985). Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infection and Immunity 47, 774-779.
Sanyal, S., Johnson, W., Jayalakshamma, B., and Green, A. (1975). Fatal "iron heart" in an adolescent: biochemical and ultrastructural aspects of the heart. Pediatrics 55, 336-341.
Schafer, A., Cheron, R., Dluhy, R., Cooper, B., Gleason, R., Soeldner, J., and Bunn, H. (1981). Clinical consequences of acquired transfusional iron overload in adults. New England Journal of Medicine 304, 319-324.
Schafer, A., Rabinowe, S., Le Boff, M., Bridges, K., Cheron, R., and Dluhy, R. (1985). Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Archives of Internal Medicine 45, 1217-1221.
Schellhammer, P., Engle, M., and Hagstrom, J. (1967). Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation 35, 631-637.
Weinberg, E. (1978). Iron and infection. Microbial Reviews 42, 46-66.
Wolfe, L., Olivieri, N., Sallan, D., Colan, S., Rose, V., Propper, R., Freedman, M., and Nathan, D. (1985). Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. New England Journal of Medicine 312, 1600-1603.